Abstract Title
Saving Life and Limb: Increasing Solubility and Stability of Fully Human Monoclonal Antibodies to Treat Flesh-Eating Infections
Additional Funding Sources
The project described was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant No. P20GM103408.
Abstract
Group A Streptococcus pyogenes (GAS) is a multi-pathogenic bacteria that posses a broad scope of infection severity. In the most extreme infections, the affected limb must be amputated, and GAS still retains a mortality rate of 24-34%. Fully human monoclonal antibodies (MAb) that are specific to a GAS virulence factor, streptolysin O (SLO), provide hope for a novel therapeutic in combating such traumas, if they can be used in high concentrations. By changing conditions of the vehicle (such as pH and excipients), we demonstrate the solubility of MAbs can be increased without altering antibody structure.
Saving Life and Limb: Increasing Solubility and Stability of Fully Human Monoclonal Antibodies to Treat Flesh-Eating Infections
Group A Streptococcus pyogenes (GAS) is a multi-pathogenic bacteria that posses a broad scope of infection severity. In the most extreme infections, the affected limb must be amputated, and GAS still retains a mortality rate of 24-34%. Fully human monoclonal antibodies (MAb) that are specific to a GAS virulence factor, streptolysin O (SLO), provide hope for a novel therapeutic in combating such traumas, if they can be used in high concentrations. By changing conditions of the vehicle (such as pH and excipients), we demonstrate the solubility of MAbs can be increased without altering antibody structure.
Comments
Sarah Hobdey is also affiliated with the Boise VA Medical Center.